difelikefalin, Kappa opioid receptor agonist, CAS No.1024828-77-0, Kappa opioid receptor agonist

Features and benefits
    Item Number
    rp173883
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp173883-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp173883-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90
    View related series
    κ receptor Agonist

    Basic Description

    Product Namedifelikefalin, Kappa opioid receptor agonist, CAS No.1024828-77-0
    Synonyms4-Piperidinecarboxylic acid, 4-amino-1-((2R)-6-amino-2-(((2R)-2-(((2R)-2-(((2R)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)- | BCP24752 | EX-A5855 | HY-17609 | MS-31091 | FE202845 | FE-202845 | D
    GradeMoligand™
    Specifications & PurityMoligand™
    Action TypeAGONIST
    Mechanism of actionKappa opioid receptor agonist

    Product Properties

    ALogP-0.6

    Associated Targets(Human)

    OPRK1 Tclin Kappa-type opioid receptor (1 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    OPRK1 Tclin Kappa opioid receptor (16155 Activities)
    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Product Specifications

    CAS1024828-77-0

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Alternate Names4-Piperidinecarboxylic acid, 4-amino-1-((2R)-6-amino-2-(((2R)-2-(((2R)-2-(((2R)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)- | BCP24752 | EX-A5855 | HY-17609 | MS-31091 | FE202845 | FE-202845 | D
    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Janecka A, Perlikowska R, Gach K, Wyrebska A, Fichna J.  (2010)  Development of opioid peptide analogs for pain relief..  Curr Pharm Des,  16  (9): (1126-35).  [PMID:20030621] [10.1021/op500134e]
    2. Cowan A, Kehner GB, Inan S.  (2015)  Targeting Itch with Ligands Selective for κ Opioid Receptors..  Handb Exp Pharmacol,  226  (13): (291-314).  [PMID:25861786] [10.1021/op500134e]
    3. Manenti L, Fenaroli P.  (2022)  Difelikefalin for pruritus associated with renal disease..  Drugs Today (Barc),  58  (9): (427-435).  [PMID:36102903] [10.1021/op500134e]

    Solution Calculators